FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) podcast

FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for the adjuvant treatment of patients with renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions

0:00
3:30
Rewind 15 seconds
Fast Forward 15 seconds
Listen to a soundcast of the November 17, 2021 FDA approval of Keytruda (pembrolizumab) for the adjuvant treatment of patients with renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.

More episodes from "FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)"

Get the whole world of podcasts with the free GetPodcast app.

Subscribe to your favorite podcasts, listen to episodes offline and get thrilling recommendations.

iOS buttonAndroid button